西米达作为一种具有不同作用机制的强效抗癌剂 (2016-2023) 的支架
Fatma Fouad Hagar1, Samar H Abbas2, Eman Atef3
1Medicinal Chemistry Department, Faculty of Pharmacy, Minia University, Minia, Egypt.
Molecular diversity
|July 20, 2024
概括
西米达化合物通过模仿核酸和与癌症标相互作用,显示出强烈的抗癌作用. 这次审查强调了它们在开发新化疗药物的潜力.
科学领域:
- 药用化学 医学化学
- 有机化学 有机化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 西米达支架表现出显著的抗癌活性,这是由于它们的结构与核酸相似.
- 它们作为键捐赠者/接受者的能力有助于它们与各种与癌症相关的药物标结合.
- 许多已批准的抗癌药物都包含了本齐米达的核心,强调了它的治疗意义.
研究的目的:
- 审查和总结西米达支架作为抗癌剂的成功应用.
- 探索基于本齐米达的药物在推进癌症治疗策略中的潜力.
- 引导药物化学家设计具有临床实用性的新型,强效化疗剂.
主要方法:
- 文献综述侧重于本齐米达衍生物及其抗癌性质.
- 分析西米达支架与多种分子的杂交和金属复合物的形成.
- 为2015年后开发的化合物编制了详细的作用机制和报告的IC50值.
主要成果:
- 西米达杂化和金属复合产生有前途的抗癌候选物.
- 详细了解这些化合物发挥细胞毒性作用的机制.
- 最近使用的基于本齐米达的抗癌药物的疗效 (IC50值) 综合数据.
结论:
- 西米达衍生物是一种多功能且有前途的抗癌药物.
- 混合化策略和金属复杂化为增强治疗疗效提供了途径.
- 进一步研究基于本齐米达的药物对未来的癌症化疗有很大的潜力.
更多相关视频
07:20Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
14.0K
05:29A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
2.8K
相关概念视频
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targets for Drug Action: Overview
6.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.1K
